The Company Signs Supply Agreement with Nectar Health Sciences Laboratory Division Inc. to provide naturally derived psilocybin for research and development of therapeutic products.
Wesana announced today that the company’s Wesana Clinics business segment has surpassed 4,000 administered ketamine treatments for major depressive disorder, anxiety, PTSD, and addiction since inception.
The state of Pennsylvania is poised to become a leader in psychedelic research after a bill known as the Public Health Benefits of Psilocybin Act was introduced recently in the House of Representatives.
Algernon Pharmaceuticals Inc. a clinical stage pharmaceutical development company, is pleased to announce that it has received positive feedback at a scientific advice meeting from the United Kingdom Medicines and Healthcare Products Regulatory Agency.
Biomind Labs Inc. announces today the Company’s completion of the development of a novel thermosensitive nasal gel delivery system for its N, N-dimethyltryptamine (“DMT”) and 5-MeO-DMT product candidates.
This article examines the results from a recent publication exploring the neuronal underpinnings of using psilocybin to treat alcohol use disorder.
Tryp Therapeutics announced today that it has received correspondence from the U.S. Food and Drug Administration related to the Company’s Investigational New Drug application for a clinical study in overeating disorders.
The Orange County Legislature is calling on the Food and Drug Administration and the State Department of Health “to promptly consider guidelines and protocols for the regulation of kratom.”
Nation’s Largest Chain of Ketamine Wellness Clinics Introduces First-of-Its-Kind Virtual Programming to Help Patients’ Loved Ones Prepare for Life After Ketamine Infusion Experience.
Silo Pharma, Inc. today announced that their joint venture partner Zylo Therapeutics received its first ketamine shipment and initiated loading ketamine into their Z-Pod® transdermal technology.